{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rilimogene+Galvacirepvec&page=2", "query": { "intervention": "Rilimogene Galvacirepvec", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rilimogene+Galvacirepvec&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rilimogene+Galvacirepvec&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T13:35:50.839Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03315871", "title": "Combination Immunotherapy in Biochemically Recurrent Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Antigen direct immunotherapy: PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "Antigen direct immunotherapy: PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "MSB0011359C (M7824)", "type": "DRUG" }, { "name": "Antigen direct immunotherapy: CV301", "type": "BIOLOGICAL" }, { "name": "CT scan of chest", "type": "DIAGNOSTIC_TEST" }, { "name": "CT scan of abdomen/pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "PSMA", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2018-03-20", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03315871" }, { "nct_id": "NCT04020094", "title": "Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "MVA-BN-Brachyury", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2019-11-20", "completion_date": "2021-04-09", "has_results": false, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020094" }, { "nct_id": "NCT00450619", "title": "153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Samarium Sm 153 lexidronam pentasodium", "type": "RADIATION" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Recombinant vaccinia-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant fowlpox-TRICOM vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 44, "start_date": "2007-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 3, "location_summary": "Chicago, Illinois • Bethesda, Maryland • New Brunswick, New Jersey", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450619" }, { "nct_id": "NCT01875250", "title": "Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "PROSTVAC-F (Fowlpox)/TRICOM", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-V (Vaccinia)/TRICOM", "type": "BIOLOGICAL" }, { "name": "Enzalutamide (Xtandi)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 38, "start_date": "2013-07-22", "completion_date": "2020-02-28", "has_results": true, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01875250" }, { "nct_id": "NCT00004029", "title": "Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "recombinant viral vaccine therapy", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 46, "start_date": "1996-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004029" }, { "nct_id": "NCT02649439", "title": "Prostvac in Patients With Biochemically Recurrent Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "PROSTVAC -V", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 97, "start_date": "2015-12-22", "completion_date": "2022-10-01", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649439" }, { "nct_id": "NCT02506114", "title": "Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "PROSTVAC V/F", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Lawrence Fong", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 15, "start_date": "2016-10-06", "completion_date": "2020-04-22", "has_results": true, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02506114" }, { "nct_id": "NCT02326805", "title": "PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Prostate Adenocarcinoma AJCC v7", "Stage II Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Rilimogene Galvacirepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 154, "start_date": "2015-06-03", "completion_date": "2022-07-20", "has_results": true, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 7, "location_summary": "Los Angeles, California • Newport Beach, California • Orange, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326805" }, { "nct_id": "NCT00005916", "title": "PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Neoplasm" ], "interventions": [ { "name": "rV-PSA", "type": "DRUG" }, { "name": "rF-PSA", "type": "DRUG" }, { "name": "rV-B7.1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2000-06-13", "completion_date": "2005-12-22", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005916" }, { "nct_id": "NCT03532217", "title": "Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Neoantigen DNA vaccine", "type": "BIOLOGICAL" }, { "name": "TriGrid Delivery System", "type": "DEVICE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "Peripheral blood", "type": "PROCEDURE" }, { "name": "Fecal samples", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2018-09-14", "completion_date": "2022-07-25", "has_results": false, "last_update_posted_date": "2022-08-05", "last_synced_at": "2026-10-04T13:35:50.839Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532217" } ] }